Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

676505 VEGFR2 Kinase Inhibitor VII, SKLB1002 - Calbiochem

Overview

Replacement Information

Key Spec Table

Empirical Formula
C₁₃H₁₂N₄O₂S₂

Products

Catalogue NumberPackaging Qty/Pack
676505-10MG Glass bottle 10 mg
Description
OverviewA cell-permeable quinazoline that acts as a potent, ATP-binding site-targeting, VEGFR2-selective inhibitor (IC50 = 32 nM), while exhibiting much reduced or little activity against 16 other kinases. An effective antiangiogenesis agent (98% inhibition of HUVEC tube formation at 10 µM; 80% inhibition of zebrafish embryos intersegmental vessel growth at 2.5 µM) that significantly suppresses SW620- and HepG2-derived tumor growth in mice (by 72% and 63%, respectively, in 18 days; 100 mg/kg/day; i.p.) in vivo.
Catalogue Number676505
Brand Family Calbiochem®
SynonymsVascular Endothelial Growth Factor Receptor 2 Kinase Inhibitor VII, SKLB1002, 6,7-Dimethoxy-4-(5-methyl-1,3,4-thiadiazol-2-ylthio)quinazoline, VEGFR Tyrosine Kinase Inhibitor XXXV
References
ReferencesZhang, S., et al. 2011. Clin. Cancer Res. 17, 4439.
Product Information
FormWhite solid
Hill FormulaC₁₃H₁₂N₄O₂S₂
Chemical formulaC₁₃H₁₂N₄O₂S₂
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Purity≥98% by HPLC
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
Toxicity Regulatory Review
Storage -20°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
676505-10MG 04055977260540

Documentation

VEGFR2 Kinase Inhibitor VII, SKLB1002 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

VEGFR2 Kinase Inhibitor VII, SKLB1002 - Calbiochem Certificates of Analysis

TitleLot Number
676505

References

Reference overview
Zhang, S., et al. 2011. Clin. Cancer Res. 17, 4439.

Brochure

Title
New Products: Volume 3, 2012
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision25-July-2012 JSW
SynonymsVascular Endothelial Growth Factor Receptor 2 Kinase Inhibitor VII, SKLB1002, 6,7-Dimethoxy-4-(5-methyl-1,3,4-thiadiazol-2-ylthio)quinazoline, VEGFR Tyrosine Kinase Inhibitor XXXV
DescriptionA cell-permeable quinazoline that acts as a potent, ATP-binding site-targeting, VEGFR2-selective inhibitor (IC50 = 32 nM), while exhibiting much reduced potency against c-kit, Ret, FMS, PDGFRα, and Aurora A (IC50 = 0.62, 2.5, 2.9, 3.1, and 3.9 µM, respectively) and little or no activity against 11 other kinases (IC50 >10 µM). An effective antiangiogenesis agent (86%, 92%, and 98% inhibition, respectively, of HUVEC migration, invasion, and tube formation at 10 µM; 80% inhibition of zebrafish embryos intersegmental vessel growth at 2.5 µM) that significantly suppresses SW620- and HepG2-derived tumor growth in mice (by 72% and 63%, respectively, in 18 days; 100 mg/kg/day; i.p.) in vivo.
FormWhite solid
Intert gas (Yes/No) Packaged under inert gas
Chemical formulaC₁₃H₁₂N₄O₂S₂
Structure formulaStructure formula
Purity≥98% by HPLC
SolubilityDMSO (2.5 mg/ml)
Storage Protect from light
-20°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Toxicity Regulatory Review
ReferencesZhang, S., et al. 2011. Clin. Cancer Res. 17, 4439.